Venus Medtech (Hangzhou) Inc. develops and commercializes transcatheter heart valve medical devices in Mainland China and internationally. The company's products include VenusA-Valve, a transcatheter aortic heart valve replacement (TAVR) product to treat severe aortic stenosis; VenusP-Valve is a transcatheter pulmonary valve system to treat the dysfunction of right ventricular outflow tract; V8/TAV8 balloon aortic valvuloplasty catheter systems; and TriGUARD3, a cerebral embolic protection device for minimizing the risk of brain damage and prevent cerebral embolism during TAVR and other structural heart disease surgeries. It also develops VenusA-Plus and VenusA-Pilot, which are TAVR product candidates; and transcatheter mitral and tricuspid valve replacement products; Liwen RF ablation system for the treatment of hypertrophic cardiomyopathy; and renal denervation for the treatment of hypertension. The company was founded in 2009 and is headquartered in Hangzhou, the People's Republic of China.

Venus Medtech (Hangzhou) Inc.

杭州启明医疗器械股份有限公司 is engaged in the research, development, and industrialization of transcatheter treatment products for structural heart diseases. The company offers a range of structural heart disease solutions, including products for aortic valve, pulmonary valve, mitral, tricuspid valve diseases, and hypertension treatment.

Metric
Company Name	Venus Medtech (Hangzhou) Inc.
Symbol	2.50K
MSH ID	COM:VENUSMEDTECH
Market	STOCKS
Sector	Healthcare
Industry	Medical - Devices
Country	CN
Stage	Private Equity Round
Employee Count	865
Website	venusmedtech.com
LinkedIn
Founders

Metric
Market Cap	316.32M
Enterprise Value
Monthly Web Traffic	2.15K
Web Traffic Growth	2.37
Valuation
Raised Capital

Metric
Revenue	67.59M
Revenue (LTM)
Revenue (NTM)
Gross Profit	53.53M
EBITDA	-70.74M
Operating Income	-81.88M
Net Income	-99.15M
EPS	-0.23
Diluted EPS	-0.23
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.79
Operating Profit Margin	-1.20
EBITDA Margin	-1.05
Net Profit Margin	-1.43
Return on Equity	-0.23
Return on Assets	-0.16
Return on Capital Employed	-0.16

COM:VENUSMEDTECH

杭州启明医疗器械股份有限公司

Last Close

5.62

23/07 20:00

Market Cap

2.46B

Beta: -

Volume Today

6.42M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-2.02
P/B Ratio	0.63
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	5.03
EV Multiple	-4.11

Metric
Days Sales Outstanding
Days Payables Outstanding	36.03
Days Inventory Outstanding	425.60
Operating Cycle	749.84
Cash Conversion Cycle	661.10
Asset Turnover	0.11

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt	-0.40
Operating Cash Flow/Sales	-0.67
Free Cash Flow Yield	-0.40

Metric
Cash & Equivalents	106.51M
Accounts Receivable
Inventory	15.53M
Goodwill	140.90M
Debt to Capitalization	0.22
Debt to Assets	0.17
Current Ratio	5.02
Quick Ratio	2.93

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue	1.30
SG&A to Revenue	0.47